中国食管癌放射治疗指南(2019年版)

2019-07-30 中国医师协会放射医师分会 国际肿瘤学杂志.2019,46(7):385-398.

随着放疗技术的快速发展,三维适形放疗、调强放疗及图像引导技术在食管癌治疗中得以广泛应用。肿瘤治疗药物进展也很快,但与放疗联合的最佳方案包括化疗、靶向或免疫及放射增敏剂仍需深入研究。我国食管癌在病因学、病理类型、高发部位等方面与欧美国家差异巨大,因此,欧美国家有关食管癌放疗的指南无法满足我国临床实践。《中国食管癌放射治疗指南》的制定将填补这一空白,其在临床实践中的推广应用并依据最新研究成果不断更新,

中文标题:

中国食管癌放射治疗指南(2019年版)

发布日期:

2019-07-30

简要介绍:

随着放疗技术的快速发展,三维适形放疗、调强放疗及图像引导技术在食管癌治疗中得以广泛应用。肿瘤治疗药物进展也很快,但与放疗联合的最佳方案包括化疗、靶向或免疫及放射增敏剂仍需深入研究。我国食管癌在病因学、病理类型、高发部位等方面与欧美国家差异巨大,因此,欧美国家有关食管癌放疗的指南无法满足我国临床实践。《中国食管癌放射治疗指南》的制定将填补这一空白,其在临床实践中的推广应用并依据最新研究成果不断更新,将会造福广大的食管癌患者。

 

拓展指南:食管癌相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=中国食管癌放射治疗指南(2019年版))] GetToolGuiderByIdResponse(projectId=1, id=65d8d1c0018035eb, title=中国食管癌放射治疗指南(2019年版), enTitle=, guiderFrom=国际肿瘤学杂志.2019,46(7):385-398., authorId=null, author=, summary=随着放疗技术的快速发展,三维适形放疗、调强放疗及图像引导技术在食管癌治疗中得以广泛应用。肿瘤治疗药物进展也很快,但与放疗联合的最佳方案包括化疗、靶向或免疫及放射增敏剂仍需深入研究。我国食管癌在病因学、病理类型、高发部位等方面与欧美国家差异巨大,因此,欧美国家有关食管癌放疗的指南无法满足我国临床实践。《中国食管癌放射治疗指南》的制定将填补这一空白,其在临床实践中的推广应用并依据最新研究成果不断更新,, cover=, journalId=null, articlesId=null, associationId=433, associationName=中国医师协会放射医师分会, associationIntro=中国医师协会放射医师分会放射医师分会成立大会暨首届放射医师论坛于2006年11月17-18日在杭州召开,中国医师协会常务副会长兼秘书长出席会议,120余名放射医师参加了会议,本次会议由浙江大学医学院附属邵逸夫医院放射科承办。首届放射医师分会共有委员40人,常委11人。放射医师分会的工作旨在提高行业人员水平,增强放射学从业人员的自律、放射学学科的准入,以及维护放射医师的权利。, copyright=0, guiderPublishedTime=Tue Jul 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>随着放疗技术的快速发展,三维适形放疗、调强放疗及图像引导技术在食管癌治疗中得以广泛应用。肿瘤治疗药物进展也很快,但与放疗联合的最佳方案包括化疗、靶向或免疫及放射增敏剂仍需深入研究。我国食管癌在病因学、病理类型、高发部位等方面与欧美国家差异巨大,因此,欧美国家有关食管癌放疗的指南无法满足我国临床实践。《中国食管癌放射治疗指南》的制定将填补这一空白,其在临床实践中的推广应用并依据最新研究成果不断更新,将会造福广大的食管癌患者。 </P> <P> </P>拓展指南:<strong>与<font color=red>食管癌</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=8d4e11c001e689e3" title="2019 ESMO临床实践指南:转移性食管癌患者的治疗(泛亚洲人群适用)" target=_blank>2019 ESMO临床实践指南:转移性食管癌患者的治疗(泛亚洲人群适用)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=62c871c001e19392" title="2019 STM专家共识:胸段食管癌手术治疗方法的选择" target=_blank>2019 STM专家共识:胸段食管癌手术治疗方法的选择</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=30c721c001681670" title="食管癌诊疗规范(2018年版)" target=_blank>食管癌诊疗规范(2018年版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=c0ac01c00166e150" title="2018 中国专家共识:食管癌放疗患者肠内营养-英文版" target=_blank>2018 中国专家共识:食管癌放疗患者肠内营养-英文版</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=40d101c00160031e" title="2018 台湾共识声明:食管癌的营养治疗" target=_blank>2018 台湾共识声明:食管癌的营养治疗</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E9%A3%9F%E7%AE%A1%E7%99%8C" target=_blank>有关食管癌更多指南</a></ul>, tagList=[TagDto(tagId=751, tagName=食管癌), TagDto(tagId=6811, tagName=放射治疗)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=40, categoryName=影像放射, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7748, appHits=793, showAppHits=11, pcHits=3874, showPcHits=4814, likes=65, shares=172, comments=12, approvalStatus=1, publishedTime=Mon Oct 14 21:55:30 CST 2019, publishedTimeString=2019-07-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Oct 14 21:55:30 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 20:13:22 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=中国食管癌放射治疗指南(2019年版))])
中国食管癌放射治疗指南(2019年版)
下载请点击:
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1180448, encodeId=3ce3118044890, content=转积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:27:31 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180446, encodeId=09ed11804465a, content=放疗与姑息的疗效对比, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:26:23 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180445, encodeId=edcc11804455c, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:25:56 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975248, encodeId=adc59e5248be, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9b41515342, createdName=kcy_city, createdTime=Sun Jun 20 22:17:40 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909934, encodeId=e80d909934f3, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74ab5395984, createdName=ms2000000761335953, createdTime=Tue Dec 22 01:58:57 CST 2020, time=2020-12-22, status=1, ipAttribution=)]
    2022-01-04 ptwins

    转积分

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1180448, encodeId=3ce3118044890, content=转积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:27:31 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180446, encodeId=09ed11804465a, content=放疗与姑息的疗效对比, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:26:23 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180445, encodeId=edcc11804455c, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:25:56 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975248, encodeId=adc59e5248be, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9b41515342, createdName=kcy_city, createdTime=Sun Jun 20 22:17:40 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909934, encodeId=e80d909934f3, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74ab5395984, createdName=ms2000000761335953, createdTime=Tue Dec 22 01:58:57 CST 2020, time=2020-12-22, status=1, ipAttribution=)]
    2022-01-04 ptwins

    放疗与姑息的疗效对比

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1180448, encodeId=3ce3118044890, content=转积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:27:31 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180446, encodeId=09ed11804465a, content=放疗与姑息的疗效对比, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:26:23 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180445, encodeId=edcc11804455c, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:25:56 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975248, encodeId=adc59e5248be, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9b41515342, createdName=kcy_city, createdTime=Sun Jun 20 22:17:40 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909934, encodeId=e80d909934f3, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74ab5395984, createdName=ms2000000761335953, createdTime=Tue Dec 22 01:58:57 CST 2020, time=2020-12-22, status=1, ipAttribution=)]
    2022-01-04 ptwins

    积分

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1180448, encodeId=3ce3118044890, content=转积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:27:31 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180446, encodeId=09ed11804465a, content=放疗与姑息的疗效对比, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:26:23 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180445, encodeId=edcc11804455c, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:25:56 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975248, encodeId=adc59e5248be, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9b41515342, createdName=kcy_city, createdTime=Sun Jun 20 22:17:40 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909934, encodeId=e80d909934f3, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74ab5395984, createdName=ms2000000761335953, createdTime=Tue Dec 22 01:58:57 CST 2020, time=2020-12-22, status=1, ipAttribution=)]
    2021-06-20 kcy_city

    学习了!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1180448, encodeId=3ce3118044890, content=转积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:27:31 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180446, encodeId=09ed11804465a, content=放疗与姑息的疗效对比, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:26:23 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180445, encodeId=edcc11804455c, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Tue Jan 04 16:25:56 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975248, encodeId=adc59e5248be, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9b41515342, createdName=kcy_city, createdTime=Sun Jun 20 22:17:40 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909934, encodeId=e80d909934f3, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74ab5395984, createdName=ms2000000761335953, createdTime=Tue Dec 22 01:58:57 CST 2020, time=2020-12-22, status=1, ipAttribution=)]
    2020-12-22 ms2000000761335953

    谢谢

    0